Search Results - "Horai, Takeshi"

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both by KATAKAMI, Nobuyuki, ATAGI, Shinji, NISHIO, Kazuto, SEKI, Yoko, EBISAWA, Ryuichi, SHAHIDI, Mehdi, YAMAMOTO, Nobuyuki, GOTO, Koichi, HIDA, Toyoaki, HORAI, Takeshi, INOUE, Akira, ICHINOSE, Yukito, KOBOYASHI, Kunihiko, TAKEDA, Koji, KIURA, Katsuyuki

“…New molecular targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both…”
Get full text

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors by Tozuka, Takehiro, Kitazono, Satoru, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Uematsu, Shinya, Yoshizawa, Takahiro, Hasegawa, Tsukasa, Uchibori, Ken, Yanagitani, Noriko, Horiike, Atsushi, Horai, Takeshi, Seike, Masahiro, Gemma, Akihiko, Nishio, Makoto

“…Dissociated responses (DR) are phenomena in which some tumors shrink, whereas others progress during treatment of patients with cancer. The purpose of the…”
Get full text

Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC by Amino, Yoshiaki, Kitazono, Satoru, Uematsu, Shinya, Hasegawa, Tsukasa, Yoshizawa, Takahiro, Uchibori, Ken, Yanagitani, Noriko, Horiike, Atsushi, Horai, Takeshi, Kasahara, Kazuo, Nishio, Makoto

“…Purpose Chemoradiotherapy (CRT) is the standard treatment for locally advanced non-small cell lung cancer (NSCLC). Recently, anti-PD-1 antibody therapy became…”
Get full text

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer by FUKUOKA, Masahiro, YANO, Seiji, EEK, Richard, HORAI, Takeshi, NODA, Kazumasa, TAKATA, Ichiro, SMIT, Egbert, AVERBUCH, Steven, MACLEOD, Angela, FEYEREISLOVA, Andrea, DONG, Rui-Ping, BASELGA, José, GIACCONE, Giuseppe, TAMURA, Tomohide, NAKAGAWA, Kazuhiko, DOUILLARD, Jean-Yves, NISHIWAKI, Yutaka, VANSTEENKISTE, Johan, KUDOH, Shinzoh, RISCHIN, Danny

“…To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor…”
Get full text

Machine learning‐based gene alteration prediction model for primary lung cancer using cytologic images by Ishii, Shuhei, Takamatsu, Manabu, Ninomiya, Hironori, Inamura, Kentaro, Horai, Takeshi, Iyoda, Akira, Honma, Naoko, Hoshi, Rira, Sugiyama, Yuko, Yanagitani, Noriko, Mun, Mingyon, Abe, Hitoshi, Mikami, Tetuo, Takeuchi, Kengo

“…Background: Understanding the gene alteration status of primary lung cancers is important for determining treatment strategies, but gene testing is both…”
Get full text

Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer by Horiike, Atsushi, Kimura, Hideharu, Nishio, Kazuto, Ohyanagi, Fumiyoshi, Satoh, Yukitoshi, Okumura, Sakae, Ishikawa, Yuichi, Nakagawa, Ken, Horai, Takeshi, Nishio, Makoto

“…Somatic mutations of epidermal growth factor receptor (EGFR) are closely associated with an objective response to EGFR tyrosine kinase inhibitors. However, it…”
Get more information

A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy by Hamanaka, Wakako, MD, PhD, Motoi, Noriko, MD, PhD, Ishikawa, Shumpei, MD, PhD, Ushijima, Masaru, PhD, Inamura, Kentaro, MD, PhD, Hatano, Satoko, Uehara, Hirofumi, MD, PhD, Okumura, Sakae, MD, Nakagawa, Ken, MD, Nishio, Makoto, MD, PhD, Horai, Takeshi, MD, PhD, Aburatani, Hiroyuki, MD, PhD, Matsuura, Masaaki, PhD, Iwasaki, Akinori, MD, PhD, Ishikawa, Yuichi, MD, PhD

“…Summary Patients with small cell lung carcinoma (SCLC) rarely demonstrate long-term survival. We previously reported that gene expression profiling identified…”
Get full text

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases by Tozuka, Takehiro, Kitazono, Satoru, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Uematsu, Shinya, Yoshizawa, Takahiro, Hasegawa, Tsukasa, Ariyasu, Ryo, Uchibori, Ken, Yanagitani, Noriko, Horai, Takeshi, Seike, Masahiro, Gemma, Akihiko, Nishio, Makoto

“…Background The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases…”
Get full text

Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non‐small cell lung cancer by Hida, Toyoaki, Tamiya, Motohiro, Nishio, Makoto, Yamamoto, Nobuyuki, Hirashima, Tomonori, Horai, Takeshi, Tanii, Hiromi, Shi, Michael M., Kobayashi, Ken, Horio, Yoshitsugu

“…ASA404 (5,6‐dimethylxanthenone‐4‐acetic acid, vadimezan), a flavone‐8‐acetic acid analogue, is a novel tumor‐vascular disrupting agent. In this study, the…”
Get full text

Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study by Ohyanagi, Fumiyoshi, Horai, Takeshi, Sekine, Ikuo, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko, Nishio, Makoto, Senger, Stefanie, Morsli, Nassim, Tamura, Tomohide

“…Preliminary safety findings are presented from the open-label Phase I part of a combined Phase I/II study of BLP25 liposome vaccine (L-BLP25) in Japanese…”
Get full text

Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer by Kawakami, Kazuyoshi, Tunoda, Takashi, Takiguchi, Tomomi, Shibata, Keiko, Ohtani, Takayuki, Kizu, Junko, Nishio, Makoto, Horai, Takeshi, Hama, Toshihiro, Taguchi, Kyoji

“…No established supportive therapy to prevent and treat chemotherapy-induced peripheral neuropathy (PN) is available. Minimizing the severity of PN is therefore…”
Get more information

Recurrence Patterns in Patients With Early Stage Non-Small Cell Lung Cancers Undergoing Positive Pleural Lavage Cytology by Satoh, Yukitoshi, MD, PhD, Hoshi, Rira, CT, Ishikawa, Yuichi, MD, PhD, Horai, Takeshi, MD, PhD, Okumura, Sakae, MD, Nakagawa, Ken, MD

“…Background Cytologic approaches such as pleural lavage cytology (PLC) are considered as possible aids to assessing prognosis of lung cancers. However, there is…”
Get full text

Discriminant model for cytologic distinction of large cell neuroendocrine carcinoma from small cell carcinoma of the lung by Hoshi, Rira, Furuta, Noriyuki, Horai, Takeshi, Ishikawa, Yuichi, Miyata, Satoshi, Satoh, Yukitoshi

“…To establish cytologic criteria for pulmonary large cell neuroendocrine carcinoma (LCNEC), we developed and evaluated a discriminant model for cytologic…”
Get more information

Early detection of lung cancer with laser-induced fluorescence endoscopy and spectrofluorometry by Kusunoki, Y, Imamura, F, Uda, H, Mano, M, Horai, T

“…We performed a clinical trial of laser-induced fluorescence endoscopy (LIFE) for detection of precancerous lesions and cancer including carcinoma in situ…”
Get more information

Cytological Characteristics of Pulmonary Pleomorphic and Giant Cell Carcinomas by Hiroshima, Kenzo, Dosaka-Akita, Hirotoshi, Usuda, Katsuo, Ogura, Shigeaki, Kusunoki, Yoko, Kodama, Tetsuro, Saito, Yasuki, Sato, Masami, Tagawa, Yutaka, Baba, Masayuki, Hirano, Takashi, Horai, Takeshi, Matsuno, Yoshihiro

“…Objective: To establish cytological features of pulmonary pleomorphic carcinoma (PC) or giant cell carcinoma (GC), we evaluated the cytological characteristics…”
Get full text

Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study) by Imamura, Fumio, Nishio, Makoto, Noro, Rintaro, Tsuboi, Masahiro, Ikeda, Norihiko, Inoue, Akira, Ohsaki, Yoshinobu, Kimura, Yukio, Nishino, Kazumi, Uchida, Junji, Horai, Takeshi

“…Gemcitabine combined with carboplatin (CG) is one of the regimens used widely for advanced non-small cell lung cancer. Improvement in its toxicity may result…”
Get more information

Cytological characteristics of pulmonary large cell neuroendocrine carcinoma by Hiroshima, Kenzo, Abe, Shosaku, Ebihara, Yoshiro, Ogura, Shigeaki, Kikui, Masanori, Kodama, Tetsuro, Komatsu, Hikotaro, Saito, Yasuki, Sagawa, Motoyasu, Sato, Masami, Tagawa, Yutaka, Nakamura, Shinobu, Nakayama, Tomio, Baba, Masayuki, Hanzawa, Suguru, Hirano, Takashi, Horai, Takeshi

“…To establish cytological features of pulmonary large cell neuroendocrine carcinoma (LCNEC), we evaluated the cytological characteristics of LCNEC. Samples from…”
Get full text

Correlation between morphology and EGFR mutations in lung adenocarcinomas by Ninomiya, Hironori, Hiramatsu, Miyako, Inamura, Kentaro, Nomura, Kimie, Okui, Michiyo, Miyoshi, Tatsu, Okumura, Sakae, Satoh, Yukitoshi, Nakagawa, Ken, Nishio, Makoto, Horai, Takeshi, Miyata, Satoshi, Tsuchiya, Eiju, Fukayama, Masashi, Ishikawa, Yuichi

“…Summary The presence of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) mutations significantly correlates with tumor sensitivity to TK…”
Get full text

Gefitinib Efficacy Associated with Multiple Expression of HER Family in Non-small Cell Lung Cancer by NISHIO, Makoto, TAGUCHI, Fumiko, OHYANAGI, Fumiyoshi, HORIKIKE, Atushi, ISHIKAWA, Yuichi, SATOH, Yukitoshi, OKUMURA, Sakae, NAKAGAWA, Ken, NISHIO, Kazuto, HORAI, Takeshi

“…The aim of this study was to compare the relationship between HER family expression and clinical response to gefitinib. Patients and Methods: Tissues from…”
Get full text

Micropapillary clusters in early‐stage lung adenocarcinomas by Hoshi, Rira, Tsuzuku, Masafumi, Horai, Takeshi, Ishikawa, Yuichi, Satoh, Yukitoshi

“…BACKGROUND It is known that patients who have pulmonary adenocarcinomas with a pathologic micropapillary pattern (pMPP) featuring small papillary tufts that…”
Get full text